Text Size

Ritanserin in Treatment of Cocaine Dependence - 1

This study has been completed.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
James Cornish, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00000187
First received: September 20, 1999
Last updated: February 28, 2013
Last verified: February 2013
History of Changes
  Purpose

The purpose of this study is to assess ritanserin as a pharmacotherapy for cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
 Drug: Ritanserin
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Ritanserin in Treatment of Cocaine Dependence

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Cocaine use
  • Cocaine craving

Enrollment: 80
Study Start Date: July 1992
Primary Completion Date: June 1994 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   28 Years to 47 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000187

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: James Cornish, M.D. University of Pennsylvania
  More Information

Publications:

Responsible Party: James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000187     History of Changes
Other Study ID Numbers: NIDA-00144-1, 3R01DA012268, K20-00144-1
Study First Received: September 20, 1999
Last Updated: February 28, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Ritanserin
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
 Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Anti-Anxiety Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents

ClinicalTrials.gov processed this record on May 16, 2013